Victory Capital Management Inc. cut its position in shares of IVERIC bio, Inc. (NASDAQ:ISEE) by 9.6% in the second quarter, Holdings Channel reports. The institutional investor owned 11,520 shares of the company’s stock after selling 1,221 shares during the period. Victory Capital Management Inc.’s holdings in IVERIC bio were worth $73,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its position in shares of IVERIC bio by 0.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,163,192 shares of the company’s stock valued at $13,369,000 after buying an additional 9,520 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in IVERIC bio by 31.8% during the 2nd quarter. New York State Common Retirement Fund now owns 78,263 shares of the company’s stock worth $494,000 after purchasing an additional 18,863 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in IVERIC bio in the 1st quarter valued at $40,000. UBS Asset Management Americas Inc. raised its holdings in IVERIC bio by 37.4% in the 1st quarter. UBS Asset Management Americas Inc. now owns 78,851 shares of the company’s stock valued at $487,000 after acquiring an additional 21,451 shares in the last quarter. Finally, DAFNA Capital Management LLC raised its holdings in IVERIC bio by 30.5% in the 1st quarter. DAFNA Capital Management LLC now owns 89,951 shares of the company’s stock valued at $556,000 after acquiring an additional 21,000 shares in the last quarter. Hedge funds and other institutional investors own 81.76% of the company’s stock.
NASDAQ:ISEE opened at $16.22 on Tuesday. The company has a market cap of $1.69 billion, a P/E ratio of -14.10 and a beta of 1.66. The stock’s fifty day moving average price is $10.30 and its two-hundred day moving average price is $7.91. IVERIC bio, Inc. has a 1 year low of $4.87 and a 1 year high of $17.03.
ISEE has been the topic of a number of research reports. Stifel Nicolaus initiated coverage on IVERIC bio in a research report on Friday, September 10th. They set a “buy” rating and a $22.00 price objective on the stock. Credit Suisse Group boosted their price objective on IVERIC bio from $15.00 to $18.00 and gave the company an “outperform” rating in a research note on Friday, September 10th. Zacks Investment Research downgraded IVERIC bio from a “hold” rating to a “sell” rating in a research note on Wednesday, June 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of IVERIC bio in a research note on Monday, September 13th.
IVERIC bio Company Profile
IVERIC bio, Inc operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R.
Want to see what other hedge funds are holding ISEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IVERIC bio, Inc. (NASDAQ:ISEE).
Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.